Quest Diagnosis, a medical testing company, announced recently of developing a new genetic test to diagnose breast cancer. The test has been named as BRC Advantage.
While reading this news, my mind took me into my childhood memories. I was 8 when my loving grandmother passed away. She died at a very early age of 50 as she was late in diagnosing her breast cancer. If she was a little more aware about the various breast cancer tests available, she might have lived longer.
The new test developed is capable of identifying BRCA1 (BReast CAncer gene one) and BRCA2 (BReast CAncer gene two), genes responsible for normal growth and functioning of the breast cells. But any kinds of abnormalities (mutations) in these cells can lead to an increased risk of breast or ovarian cancer.
Earlier a company, Myriad Genetics had a patent on these two BRCA genes which gave the company an exclusive holding on testing any mutations in these genes.
But a recent US Supreme Court ruling has invalidated this patent thus making the two BRCA genes available to other companies for developing their own tests. Breast Cancer Therapies Markets
And why not? A naturally occurring gene is a nature’s product and not a mere patent. And very soon the Supreme Court’s decision seems to be showing results with Quest Diagnosis coming with its first such test called BRC Advantage. The test is currently available in 49 US states and more than 2100 service centers. Quest Diagnosis hopes to increase the availability of these tests at high risking populations.
Reading about this new breast cancer test, questions still keep pouring in my mind that even after enough number of tests available, are we women actually aware about them?
Medical Devices Reports
Artificial Kidneys Promise Freedom for Dialysis Patients and Savings for Hospitals
The Wearable Artificial Kidney (WAK) will offer patients across the world suffering from kidney failure freedom from endless hospital appointments – and hospitals the chance to save on resources – states a new report by medical industry experts GBI Research.
The new report, “Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis” shows the growing prevalence of diabetes and hypertension, alongside an increasingly large elderly population, has meant that doctors have encountered a rapid growth in the number of patients suffering from End Stage Renal Disease (ESRD), which has put pressure on burgeoning healthcare budgets. However, the lucrative market these patients represent for dialysis device manufacturers has led to the development of the WAK, the latest innovation to provide patient care on a global scale.
One in 10 adults are at risk of chronic kidney disease (CKD), totaling roughly 500 million people worldwide, and the rising diabetic population is increasing the prevalence of diabetic nephropathy, which is a leading cause of CKD and ESRD. Serious kidney damage demands medical attention, and the Wearable Artificial Kidney (WAK) is the latest treatment option, offering continuous dialysis treatment to patients with ESRD by using nanomaterials such as carbon nanotubes to imitate normal kidney function. Individuals gain a dramatically improved quality of life, as treatment requires minimal patient intervention.
The global renal dialysis equipment market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 6% to $12.7 billion during 2010-2017. Dialysis accessories will continue to be the largest sub-segment, and will grow at a CAGR of 6% during the forecast period..
In this market research report, Kalorama Information defines the current opportunity and a realistic future potential for personalized medicine in clinical testing. In addition to analysis of tests currently on the market and in development, the report profiles key competitors and discusses trends that are important for understanding this much-discussed growth area of the diagnostic industry.
The concept of ‘Personalized Medicine’, as seen by Kalorama clinical diagnostics industry analyst Shara Rosen, is currently somewhere between dream and road to reality. Fantastic promises have been made over the years in the press and reports of startup concerns. However, slowly but surely real revenues are appearing, and realistic models for future growth will be seen.
Developments that are linked in the press to ‘personalized medicine’ are many, and can at times be confusing. But there are several discovered biomarkers that are important in diagnostic markets.
Biomarkers discussed in the report include:
Cytochrome P450 and Drug Metabolism
Estrogen Receptor and Progesterone
Receptor Status for Breast Cancer
HER2 Overexpression and Herceptin and Tykerb
Epidermal Growth Factor Receptor (EGFR)
KRAS Mutations and Anti-EGFR Therapy for Colorectal Cancer
BRAF Mutations and Cancer Therapy
UGT1A1 Genetic Variants
PIK3CA Genetic Variation
KIF6 Genetic Variation
ALK Genetic Variation
This is a highly active market. A special focus of the report is the bustle of activity with collaborations between IVD and pharmaceutical companies, as well as IVD companies and CLIA labs. This report profiles scores of such companies operating in this market and estimates and forecasts markets (where there are products on the market) for personalized medicine technologies in the following categories:
Cardiac Markers, immunoassays Cardiac Risk Markers
Cardiac markers, molecular Coagulation, routine Coagulation, molecular Cancer, Tumor Markers Cancer, Molecular Cancer, Tissue-based Psychiatric Disorders Diabetes, BGM Diabetes, HbA1c Microbiology, ID/AST Infectious Diseases, Viral Load (HIV, HCV, HBV)
Infectious Diseases, other Blood Bank Molecular Transplant Tissue Typing Lab Developed Tests
Request for Sample Page More about this Report…
| Global Nucleic Acid Testing Market: Facilities, Test Volumes, and Sales Forecasts by Country
| 2012 Global Endocrine Function Testing Market Outlook: Growth Opportunities and Strategies
| 2012 Global CA Tumor Markers Diagnostics Market Outlook: Test Volumes, Sales Forecasts, and Supplier Shares by Country
| 2012 Global Immunoprotein Testing Market Outlook: Growth Opportunities and Strategies
| Advances in Drug-Diagnostic Co-Development
| 2012 European Microbiology Testing Market: France, Germany, Italy, Spain, UK Emerging Opportunities and Business Expansion Strategies
| Advances in Imaging Biomarkers: Innovative technologies, applications in R&D and clinical practice, and informatics and regulatory requirements